C
Cardiff Oncology D
D
CRDF
0.91590
USD
0.01
(0.89%)
Pre Open·0.91490USD-0.00100(-0.11%)
Volume
8,369
EPS
-1
Div Yield
-
P/E
-2
Market Cap
71,252,669
Title: Cardiff Oncology
Sector: Healthcare
Industry: Biotechnology
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigationin other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.